An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia



Status:Archived
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2009
End Date:December 2010

Use our guide to learn which trials are right for you!

An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.


This observational study will monitor and register infusion-related adverse events and their
handling in patients with chronic lymphocytic leukemia on treatment with MabThera
(rituximab). Data will be collected from patients receiving intravenous MabThera at a dose
of 375mg/m2 in cycle 1 and 500mg/m2 in subsequent cycles at each treatment visit for up to 6
months. Target sample size is 100 patients.



We found this trial at
1
site
South San Francisco, California
?
mi
from
South San Francisco, CA
Click here to add this to my saved trials